BioRestorative Therapies, Inc. announced the resignations of CEO Lance Alstodt, CFO Robert Kristal, and Director David Rosa, effective July 13, 2026. Katharyn Field was appointed as CEO, President, and interim CFO, Treasurer, and Secretary. The company is investigating the validity of the executives' claims of a Change in Control that would trigger approximately $2.85 million in severance. BioRestorative Therapies, Inc. is a biotechnology company focused on developing cell therapy products.

On June 10, 2026, BioRestorative Therapies, Inc. entered into an employment agreement with Francisco Silva, Vice President of Research and Development. The agreement runs through June 10, 2029, and maintains Mr. Silva's annual salary at $575,000. The company operates in the biotechnology industry and develops regenerative medicine therapies.

BioRestorative Therapies, Inc. entered into a $1,000,000 revolving loan agreement with Bowery Group LLC on June 10, 2026, which carries a 12% annual interest rate. As part of the agreement, Francisco Silva, Nickolay Kukekov, and Patrick F. Williams resigned from the Board of Directors, and the company has appointed Mika Grasso, Katharyn Field, and Jatinder Dhaliwal as new directors. BioRestorative Therapies, Inc. is a biotechnology company focused on cell therapy development.